Trial Profile
Fluocinolone Acetonide in Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms FAME
- Sponsors Alimera Sciences
- 08 Feb 2024 According to an Alimera Sciences media release, the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending that patients with a natural lens (phakic patients) being treated for chronic diabetic macular edema (DME) have access to ILUVIEN 190 microgram intravitreal implant in applicator (fluocinolone acetonide).
- 11 Jul 2018 According to an Alimera Sciences media release, data from this study will be presented at the 36th Annual Meeting of the American Society of Retina Specialists (ASRS) 2018.
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.